Media headlines about Urogen Pharma (NASDAQ:URGN) have been trending somewhat positive on Monday, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Urogen Pharma earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.7074930679471 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Urogen Pharma (NASDAQ:URGN) opened at $36.82 on Monday.
Several research firms recently issued reports on URGN. Oppenheimer Holdings, Inc. set a $32.00 price objective on Urogen Pharma and gave the company a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research cut Urogen Pharma from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. Finally, Jefferies Group LLC upped their price objective on Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, October 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $28.50.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/11/06/urogen-pharma-urgn-receives-daily-coverage-optimism-score-of-0-20.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
What are top analysts saying about Urogen Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Urogen Pharma and related companies.